Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive resultsRamat Gan, Israel, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Can-Fite
Can-Fite submitted paperwork to test a new medicine for a rare disease in children at a hospital in Italy. When a company moves from planning to real-world testing, it shows progress—but we have to wait and see if the medicine actually works before knowing if it matters.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.